Alchemist vs FSD Pharma Which Offers More Value?

Alchemist and FSD Pharma are two prominent companies in the pharmaceutical industry, known for their innovative approaches to drug development and research. Alchemist is recognized for its expertise in creating cutting-edge therapies for various medical conditions, while FSD Pharma focuses on cannabis-based products and treatments. Both companies have garnered significant attention from investors seeking opportunities in the rapidly growing pharmaceutical sector. The competition between Alchemist and FSD Pharma stocks has sparked interest and debate among industry analysts and traders alike.

Alchemist or FSD Pharma?

When comparing Alchemist and FSD Pharma, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Alchemist and FSD Pharma.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Alchemist has a dividend yield of -%, while FSD Pharma has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Alchemist reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, FSD Pharma reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Alchemist P/E ratio at 152.03 and FSD Pharma's P/E ratio at -0.27. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Alchemist P/B ratio is 0.68 while FSD Pharma's P/B ratio is 0.30.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Alchemist has seen a 5-year revenue growth of 0.20%, while FSD Pharma's is -1.00%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Alchemist's ROE at 0.45% and FSD Pharma's ROE at -94.58%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are ₹21.50 for Alchemist and $0.09 for FSD Pharma. Over the past year, Alchemist's prices ranged from ₹4.43 to ₹21.50, with a yearly change of 385.33%. FSD Pharma's prices fluctuated between $0.09 and $109.19, with a yearly change of 125409.77%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.